ACR 50 response of DMARDs naive patients Number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).
1 finding from 1 review
ACR 50 response of MTX inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
ACR 50 response of non‐MTX DMARDs inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of DMARDs naive patients number of withdrawals · patients with rheumatoid arthritis
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of DMARDs naive… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of MTX inadequate responders number of withdrawals · patients with rheumatoid arthritis
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of MTX inadequate… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs inadequate responders number of withdrawals · patients with rheumatoid arthritis
It is very uncertain whether MTX combination changes withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs… compared with MTX monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Clinical remission · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Physical function · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate leads to higher physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 compared with methotrexate monotherapy (high certainty).
1 finding from 1 review
No radiographic progression in total Genant‐modified Sharp score (range 0 to 290) Analysis 1.21 · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in no radiographic progression in total Genant‐modified Sharp score… compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events Analysis 11.2 · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review